Lifespan Vision Ventures Invests in TECregen’s Seed Financing

Norwalk, CT – January 8, 2026 - Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced an investment in TECregen’s CHF 10 million seed financing round. Lifespan Vision Ventures joins lead investor Boehringer Ingelheim Venture Fund (BIVF), along with Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank.

TECregen is developing next‑generation biologics to rejuvenate thymic epithelial cells (TECs) and rebuild thymic function. Age‑related thymic involution weakens T‑cell production, and this regenerative biologic platform aims to strengthen immune resilience and address age‑related immune decline.

“We are delighted to welcome Lifespan Vision Ventures as part of our seed investor group,” said Filippo Oliveri, Co-Founder and Board Director of TECregen. “Their focus on longevity and healthspan aligns well with TECregen’s mission, and this strong investor syndicate provides important support as we advance our thymus regeneration platform toward the clinic.”

“TECregen’s thymus-rejuvenating biologics address one of the fundamental drivers of immune aging, and their innovative approach has the potential to rebuild immune resilience and support healthy aging,” said Harry Robb, Principal at Lifespan Vision Ventures. “We’re pleased to support the company in bringing such innovation to patients who need them most.”

About TECregen

TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells and achieve durable improvements in immune function. By developing a pipeline of differentiated thymopoietic biologics, TECregen aims to strengthen immune recovery following transplantation or cytotoxic therapy, promote immune health, and enhance immune surveillance against cancer, ushering in a new era of immunotherapy.

About Lifespan Vision Ventures

Lifespan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space.

Contact: info@lifespanvision.com